News & Events

New Independent Data on Adherium Smartinhaler Clinical Outcomes in Paediatric Asthma to be Presented at European Respiratory Congress

New Independent Data on Adherium Smartinhaler Clinical Outcomes in Paediatric Asthma to be Presented at European Respiratory Congress

Melbourne, Australia, 25 September: Adherium Limited (ASX: ADR), a global leader in digital health technologies which address sub-optimal medication use in chronic disease; today announced that data from three independent studies demonstrating the efficacy of the Company’s Smartinhaler™ platform in paediatric asthma management will be presented at the European Respiratory Congress, taking place between 26-30 September in Amsterdam, The Netherlands.

Data from the following studies will be presented as part of Oral Presentation Session 499 Paediatric asthma and allergy: e-health in management, taking place on 30 September in Room 2.1:

Randomised control trial to investigate whether electronic adherence monitoring with reminder alarms and feedback can improve clinical outcomes in childhood asthma
Presenter: Dr Robert Morton (Clinical Research Fellow, University of Sheffield)
Time: 9:00
Abstract number: OA4772

Exploring the attitudes of adolescents with asthma towards monitoring and sharing of data on their inhaler use
Presenter: Mr Sam Howard (PhD student, University of Nottingham)
Time: 9:15
Abstract number: OA4773

Improvement in asthma control and airway inflammation during a period of electronic monitoring
Presenter: Dr Anja Jochmann (Royal Brompton & Harefield NHS Foundation Trust)
Time: 9:45
Abstract number: OA4775


Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease.

The Company’s proprietary Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease.

Adherium has the broadest range of "smart" medication sensors for respiratory medications globally. Adherium Smartinhaler™ medication sensors attach to prescription inhalers to provide reminders and monitoring of inhaler usage.

The SmartinhalerLive™ platform uses wireless communications technology to provide real time data collection and reporting from Smartinhaler™ sensors.

Currently clinicians do not have a system to record medication usage and rely heavily on patient feedback, which can be inaccurate. Having access to accurate and objective data enables physicians to identify sub-optimal medication adherence and suggest more effective treatment plans for patients.

Clinical outcomes data has proven that the Smartinhaler platform can improve adherence by up to 59% in adults and 180% in children with asthma. In addition, severe episodes were reduced by 60% in adults with asthma. Both groups benefited from improved quality-of-life as a result of their improved adherence, demonstrating a substantial gain over current best practice treatment.

The Smartinhaler™ platform has so far been used in 40 projects (clinical, device validation or other) and has peer reviewed clinical outcomes data resulting from 14 studies. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.

Adherium is a provider of digital health solutions to pharmaceutical, remote patient monitoring and clinical trials companies and organisations.

Issued for and on behalf of Adherium by Instinctif Partners.
For more information please contact:

back to news


Sue CharlesManaging Partner